Insmed

1. BRINSUPRI brensocatib FDA decision2H 2026BRINSUPRI brensocatib FDA decision, 2H 2026, material
2. ARIKAYCE Japan filing2H 2026ARIKAYCE Japan filing, 2H 2026, notable
3. TPIP PPF Ph3 start2H 2026TPIP PPF Ph3 start, 2H 2026, routine
4. TPIP IPF Ph3 start1H 2027TPIP IPF Ph3 start, 1H 2027, routine
5. Insmed corporate update2027Insmed corporate update, 2027, routine
6. ARIKAYCE FDA approvalmid-2027ARIKAYCE FDA approval, mid-2027, thesis-defining
7. TPIP Ph3 topline2028TPIP Ph3 topline, 2028, major
8. Pharmakon debt corporate updateJan 3, 2028Pharmakon debt corporate update, Jan 3, 2028, routine
9. OrbiMed royalty financing corporate updateMar 31, 2028OrbiMed royalty financing corporate update, Mar 31, 2028, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.